Demand for Peptide Based Infection Therapeutics Market to Reach a Value of US$ 1.5 Bn by 2022

Peptide therapeutic agents are novel solutions to treat infectious diseases. The peptide based infection therapeutics market is impacted by factors such as higher investment in healthcare industry, advancements in technologies, increase in biotech and pharmaceutical companies, the need for peptides to treat infections owing to the various advantages offered by peptides such as safety, reliability, stability, higher efficacy, cost effectiveness and easy synthesis due to small size, rising developments in drug discovery and the rising foreign direct investment in emerging economies.

For detailed insights on enhancing your product footprint, request for a sample here – https://www.factmr.com/connectus/sample?flag=S&rep_id=188

All the aspects influence the global peptide based infection therapeutics market in a positive way. North America region is expected to be the most lucrative region for the global peptide based infection therapeutics market.

The global peptide based infection therapeutics market is anticipated to show a value a shade less than US$ 1.5 Bn and expected to grow at a robust rate during the period of forecast.

Forecast Highlights on Global Peptide Based Infection Therapeutics Market

• North America expected to show higher market attractiveness and domination over other regions in terms of market share by revenue. It has a higher value share and is poised to grow at a higher growth rate to reflect a CAGR of 8.4% throughout the forecast period, 2017 to 2022

For critical insights on this market, request for methodology here – https://www.factmr.com/connectus/sample?flag=RM&rep_id=188

• Asia-Pacific excluding Japan (APEJ) shows the highest growth rate and poised to register a CAGR of 8.7% during the period of forecast, owing to rapid development and higher foreign direct investment in this region. Following APEJ, Europe region also reflects good rate of growth in the global peptide based infection therapeutics market
• By drug class, telaprivir shows higher market share by revenue as compared to boceprevir. However, boceprivir shows a higher growth rate to reflect a CAGR of 8.2% during the period of forecast. It can be said that, even though telaprevir segment has a market share which is almost one and a half times than that of  boceprevir, the boseprivir segment, could match the market share at this high growth rate post 2022, a market observation which would depend on the current growth rate of boceprivir and its consistency through 2017 to 2022 and even beyond
• The online pharmacies segment by distribution channel shows the fastest growth rate and is poised to reflect a CAGR of 9.2% throughout the period of forecast of 2017 to 2022. Yet, this segment shows less market share by revenue as compared to other segments.

Market Taxonomy

Drug	Telaprevir Boceprevir
Distribution Channel	Hospital Pharmacies Retail Pharmacies Online Pharmacies

For in-depth competitive analysis, buy now – https://www.factmr.com/checkout/188

The report has also profiled leading players in the global market for peptide based infection therapeutics, which would remain active through 2022. These include companies like Parchem Fine & Specialty Chemicals, Merck & Co., Inc. and Vertex Pharmaceuticals Incorporated.

Read More Trending and Similar Reports from Fact.MR – https://www.globenewswire.com/en/news-release/2020/03/27/2007702/0/en/Tricuspid-Valve-Repair-Market-Poised-for-Astounding-Growth-Through-2029-Fact-MR-Projects-Annuloplasty-Rings-to-Remain-Top-Selling.html

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com